TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Geriatrician Nathaniel Chin says subjective cognitive decline can offer a period to investigate changes and address possible contributors before standard tests show impairment. He stresses that it is not a diagnosis of Alzheimer’s and that concerning patterns may warrant a thorough baseline and follow-up. The supplied report cuts off during its discussion of biomarkers, so it does not establish who should receive testing or what treatment may follow.
Geriatrician Nathaniel Chin says people who report persistent changes in memory or thinking should not be dismissed solely because their cognitive test scores remain within the normal range. In a report published by Being Patient on October 27, 2026, Chin describes subjective cognitive decline as a possible early period for investigating symptoms and considering prevention or treatment discussions, while emphasizing that it does not by itself mean a person has Alzheimer’s disease.
Subjective cognitive decline (SCD) refers to a person’s ongoing sense that their thinking has worsened compared with their previous ability, despite comprehensive testing finding no objective impairment. Chin, a memory-care physician at UW Health and an associate professor at the University of Wisconsin–Madison, says patients may report forgetting conversations, depending more on notes or finding that thinking takes greater effort. A normal score does not necessarily show whether someone has declined from their own earlier level.
Chin distinguishes a brief screening from a comprehensive cognitive evaluation. He says screening tests generally take five to 15 minutes and sample a limited range of abilities, while a fuller assessment often takes an hour or more and examines memory, language, attention and executive function. He also notes that test results are commonly compared with those of people of similar age, not with the individual’s past performance. Repeated testing can help show whether a person is stable or experiencing a consistent decline, he writes.
SCD is a description of an experience, not an explanation for it. Chin lists sleep problems, medications, depression or anxiety, illness, vascular disease, hearing loss, stress and normal aging as possible influences on perceived sharpness. He says clinicians should investigate such factors rather than assume Alzheimer’s is the cause. For persistent concerns, especially when several risk features are present, his proposed approach includes establishing a detailed baseline, seeking observations from someone who knows the person and reassessing over time.
Why Normal Scores May Not End the Inquiry
The report’s central point is about the gap between a person’s perceived change and the threshold that a test can detect. Someone whose abilities were once well above average might lose ground while still scoring in the average range, Chin explains. That makes the person’s history and changes across repeated evaluations relevant alongside a single test result.
For patients and families, the distinction may affect whether they seek follow-up and whether clinicians investigate reversible or treatable contributors to symptoms. Chin argues against telling a person simply to return if things worsen when their concerns are persistent. At the same time, SCD does not establish Alzheimer’s, and the report does not say that every person with subjective concerns needs biomarker testing or treatment. Its practical message is closer monitoring and a fuller assessment, not a diagnosis based on worry alone.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes and Travel Case, White
As an affiliate, we earn on qualifying purchases.
Features That Can Raise Concern
Chin discusses the concept of “SCD plus,” developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. The features described in the report include memory-focused concerns, onset within the past five years, onset at age 60 or older, worry about the change, persistence, seeking medical help and confirmation from someone familiar with the person’s abilities.
These features are not proof of Alzheimer’s, Chin says. Their presence in combination can make a closer evaluation more appropriate. The article contrasts a person with longstanding, intermittent word-finding worries linked to stress or poor sleep with someone over 60 who reports a clear recent memory change, remains concerned, seeks evaluation and has a spouse who has noticed the same change. Both might test within normal ranges, but Chin says the patterns warrant different clinical attention.
The supplied report also begins to discuss whether blood tests, cerebrospinal fluid testing and amyloid PET can identify Alzheimer’s-related biology before cognitive impairment. However, the source text provided here ends before that section is complete. It does not provide eligibility guidance, test-performance details, recommendations or a conclusion about the role of those methods.
What SCD Cannot Establish
The cause of subjective decline is often unclear from a person’s report alone. The symptoms may relate to Alzheimer’s, but Chin lists several other possible contributors, and the supplied material does not provide a method for determining the cause in an individual case.
The article excerpt does not set out how frequently SCD progresses to measurable impairment, how accurately any biomarker test identifies Alzheimer’s in people with normal cognitive testing, or which patients should be tested. It also does not explain what prevention or treatment is appropriate at this stage. The SCD-plus features are described as factors that can raise concern, not as a diagnostic checklist that confirms disease.
Follow-Up and Biomarker Questions
Chin’s suggested next steps for persistent concerns are a thorough cognitive baseline, assessment of other possible contributors, input from a knowledgeable family member or friend when available, and repeat testing over time. The report raises biomarker testing as a further question for selected patients, mentioning blood biomarkers, cerebrospinal fluid testing and amyloid PET, but the supplied excerpt does not include his recommendations about their use.
For readers, the development described is a physician’s clinical perspective, not a new guideline or a reported change in medical policy. What happens next for an individual depends on clinical assessment; the source does not specify a standard follow-up schedule or a treatment pathway. Any decisions about evaluation or testing should be discussed with a qualified health professional.
Key Questions
What is subjective cognitive decline?
SCD is a persistent sense that memory or thinking has declined from a person’s previous level, even though comprehensive testing does not find objective impairment. It describes the person’s experience; it does not identify the cause.
Does subjective cognitive decline mean someone has Alzheimer’s?
No. Chin says SCD itself is not an Alzheimer’s diagnosis. Sleep, medications, mood, illness, hearing loss, stress and other factors can affect perceived thinking ability.
Why might a person have normal test results but still notice a change?
A test may compare a person with peers of a similar age rather than with their own earlier performance. Chin says someone can decline from a high previous level and still score within the average range, which is one reason repeated assessment can be informative.
What does “SCD plus” mean?
It refers to features that may make subjective concerns more worthy of closer attention, such as recent onset, persistent memory-focused worries, concern about the change and confirmation by someone who knows the person. These features do not prove Alzheimer’s.
Can biomarkers detect Alzheimer’s before cognitive impairment?
The report raises that question and names blood biomarkers, cerebrospinal fluid testing and amyloid PET. The supplied source text ends before providing findings or recommendations, so it does not establish who should be tested or what a result would mean for an individual.
Source: beingpatient.com
